There are 2789 resources available
983P - Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Presenter: Nuria Kotecki
Session: ePoster Display
918P - Impact of locally advanced head and neck cancer treatment: Is there a role for exercise? FIT4TREAT
Presenter: Ines Leao
Session: ePoster Display
919P - Survival impact of nutritional status of locally advanced head and neck cancer squamous cell carcinoma (HNSCC) patients treated with chemoradiotherapy: A prospective observational study
Presenter: Ratchadakorn Meesart
Session: ePoster Display
Current landscape: Did we learn how to select first-line strategy?
Presenter: Edward Garon
Session: Refining the use of immune-checkpoint inhibition
Resources:
Slides
Webcast
Mechanisms of resistance and novel strategies
Presenter: Céline Mascaux
Session: Refining the use of immune-checkpoint inhibition
Resources:
Abstract
Slides
Webcast
Do we have any idea how to use these drugs in oncogene addicted patients yet?
Presenter: Julien Mazieres
Session: Refining the use of immune-checkpoint inhibition
Resources:
Slides
Webcast
Introduction
Presenter: Sanjay Popat
Session: The year in review of molecularly driven NSCLC
Resources:
Slides
Broadening the horizons: EGFR, ALK, ROS-1, BRAF
Presenter: Christine Lovly
Session: The year in review of molecularly driven NSCLC
Resources:
Slides
Webcast
Opening new horizons: RET, NTRK, MET, HER2…
Presenter: Herbert Ho Fung Loong
Session: The year in review of molecularly driven NSCLC
Resources:
Slides
Webcast
How do we identify resistance mechanisms?
Presenter: Joop De Langen
Session: The year in review of molecularly driven NSCLC
Resources:
Slides
Webcast